Although immunotherapy has significantly improved the overall survival rate in advanced NSCLC when compared to conventional treatments, less than half of the patients respond (including those with >50% PD-L1 expression on tumor cells), and the 3-year survival rate is significantly lower in patients without actionable mutations5. The gene discussed is CD274; the disease is neoplasm.